Uppsala, Sweden, 2012-03-08 08:56 CET (GLOBE NEWSWIRE) --
THE PERIOD May 1, 2011 – January 31, 2012
- Consolidated net sales amounted to € 100 thousand (12) [1]
- Operating income amounted to € -5,183 thousand (-4,787)
- Net income after tax amounted to € -5,162 thousand (-4,995)
- Earnings per share was € -0.10 (-0.12)
- Comprehensive income amounted to € -5,162 thousand (-4,995)
THIRD QUARTER November 1, 2011 – January 31, 2012
- Consolidated net sales amounted to € 0 thousand (7)
- Operating income amounted to € -1,952 thousand (-1,747)
- Net income after tax amounted to € -1,937 thousand (-1,756)
- Earnings per share was € -0.03 (-0.04)
- Comprehensive income amounted to € -1,937 thousand (-1,756)
- On-going extension of patent protection
- Paccal® Vet was granted MUMS-designation by the FDA for the indication mammary carcinoma (breast cancer in dogs)
[1]The numbers in parentheses concerns results for the corresponding period previous year
Weine Nejdemo, CFO, Tel: +46 18 50 54 40 e-mail:info@oasmia.com www.oasmia.com
